Medical affairs, market access, HEOR, clinical operations working in biomedical or pharmaceutical companies.
Real-world evidence (RWE) research is an increasingly important component of biopharmaceutical product development and commercialization. The growing industry need for broader information on real-world effectiveness and safety—both of which will impact the eventual reimbursement and utilization of new products—is driven by regulators, public and private payers, and prescribers, all of whom seek to better understand the value of a new product in a real-world setting. The result is that real-world evidence is now included earlier in the research and development phase.
Medical chart review (MCR) studies are a research technique in which pre-recorded, patient-centered data are used to answer one or more research questions and are often needed in the absence of suitable healthcare databases and/or other secondary sources of information. Chart review studies facilitate the rapid collection of clinical and healthcare resource utilization (HRU) data and provide tailored, patient-level datasets that are ideally suited as inputs to a wide range of burden of illness, drug utilization, safety, and health economic analyses.
Teaching methods: Lecture + workshop
REGISTRATION FEES: Early bird: euro 650,00 (before 24/09/2017); Ordinary: euro 750,00; Freelance,Academy,Public Administration: euro 400,00. The fee includes: tuition, teaching materials, lunch break, organizational office assistance, attendance certificate.